Rallybio Corp 2026年季度报告

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2026OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________Commission File Number: 001-40693_____________________________________ RALLYBIO CORPORATION (Exact Name of Registrant as Specified in its Charter)_____________________________________ 85-1083789 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filingrequirements for the past 90 days. YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” inRule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesNo Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the SecuritiesExchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. YesNo As of July30, 2026, the registrant had 5,310,499 shares of common stock, $0.0001 par value per share, outstanding. Table of Contents Item 1.Financial Statements7Unaudited Condensed Consolidated Balance Sheets7Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income(Loss)8Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity9Unaudited Condensed Consolidated Statements of Cash Flows11Notes to Unaudited Condensed Consolidated Financial Statements12Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations25Item 3.Quantitative and Qualitative Disclosures About Market Risk38Item 4.Controls and Procedures38 Item 1.Legal Proceedings39Item 1A.Risk Factors39Item 2.Unregistered Sales of Equity Securities and Use of Proceeds92Item 5.Other Information93Item 6.Exhibits94Signatures95 Cautionary Note Regarding Forward-Looking StatementsThis Quarterly Report on Form 10-Q contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements other than statements of historicalfacts contained in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identifyforward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,”“project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or othersimilar expressions, although not all forward-looking statements contain these words. Forward-looking statements include,but are not limited to, statements concerning: •our proposed Merger (as defined below) with Avenzo Therapeutics, Inc, a Delaware corporation ("Avenzo") andany potential benefits of the merger; •the initiation, timing, progress, results, and cost of our research and development programs, and our current andfuture preclinical and clinical studies, including statements regarding timing of initiation and completion of ourclinical trials for RLYB116, and related preparatory work, and the period during which the results of the trials willbecome available; •the success, cost and timing of the clinical development of our product candidates, including RLYB116; •the potential of our product candidates to treat certain target diseases; •our ability to initiate, recruit and enroll patients in and conduct our clinical trials at the pace that we project; •our ability to compete with companies currently marketing or engaged in the development of treatments fordiseases that our product candidates are designed to target, including diseases of complement dysregulation,diseases of iron overload, immune platelet transfusion refractoriness ("PTR") and refractory antiphospholipidsyndrome ("APS"); •our reliance on t